



an Open Access Journal by MDPI

Fish as Model Organism for the Identification of Marine Bioactive Compounds

Guest Editor:

Prof. Dr. M. Leonor Cancela

Ctr Marine Sci CCMAR, Univ
Algarve, 8005-139 Faro, Portugal

Deadline for manuscript
submissions:

closed (30 June 2022)

Message from the Guest Editor

Dear colleagues,

Zebrafish (*Danio rerio*) and medaka (*Oryzias latipes*) are currently used as model organisms for the screening of molecules of interest for biomedical and pharmaceutical applications, and, in particular, for the identification of compounds capable of rescuing fish phenotypes mimicking human diseases. The marine environment, with its large diversity of habitats, hosts a plethora of species with a large diversity of physiological adaptations, which are the source of structurally unique natural products. In recent years, a number of molecules/extracts with specific biomedical applications have been isolated from marine organisms, and these proven to be effective in targeting prevalent and rare diseases or as sources to develop new analgesics, anti-inflammatory or antidiabetic drugs, to name only a few. The present Special Issue aims to bring together articles presenting a comprehensive overview of the use of fish as model organisms to identify marine derived compounds of biomedical interest.

Dr. M. Leonor Cancela

Guest Editor



mdpi.com/si/76925

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Contact Us

Marine Drugs Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
[X@Marine_Drugs](#)